Cutaneous Oncology

Melanoma

Unresectable Stage III-IV

Any Line

1st Line

Previously treated with anti PD-1

MEL023 Phase III IMO-2125 + Ipilimumab vs Ipilimumab Alone in Anti-PD-1 Refractory Melanoma

PI: Reddy Idera Pharmaceuticals

ECOG-ACRIN-E06141 Phase II/III Nivolumab & Ipilimumab +/-Sargramostim in Unresectable Stage III/IV Melanoma

PI: Reddy ECOG-ACRIN

Requires Injectable Lesions

BRAF +

Receiving Palliative Radiation

MEL0019 Phase III PDR001 + Dabrafenib + Trametinib vs Placebo + Dabrafenib + Trametinib in BRAF V600 Mutant Melanoma

PI: Reddy Novartis

V600 Wildtype

MEL0022 Phase III Cobimetinib + Alezolizumab vs Pembrolizumab in Previously Un-Treated BRAF V600 Wild-Type Melanoma

PI: Reddy (Pending)

MEL0015 Phase I Ipilimumab & Nivolumab (Blockade) + External Beam Radiotherapy in Stage IV Melanoma

PI: Knox Ludwig Institute for Cancer Research

MEL0002 Phase II/III Intratumoral SD-101 + Pembrolizumab in Metastatic Melanoma or Recurrent /Metastatic HNSCC

PI: Reddy Dynavax Technologies Corporation

KEY

Pending

Open for Enrollment

Observational Study

Optional Path

Trial Posting

Extension Study

Immunotherapy

Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu